DiaMedica Therapeutics, Inc. (DMAC)
8.55
+0.24
(+2.89%)
USD |
NASDAQ |
Feb 24, 16:00
8.55
0.00 (0.00%)
Pre-Market: 20:00
DiaMedica Therapeutics Research and Development Expense (Quarterly) : 6.437M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| XOMA Royalty Corp. | 0.069M |
| Avantor, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 87.83M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| Savara, Inc. | 20.59M |